Abstract
Objective To investigate the clinical effect of teysuno combined with apatinib on advanced gastric cancer and its influence on tumor markers. Methods Sixty-eight patients with advanced gastric cancer in Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine from January 2016 to October 2017 were selected, and they were divided into two groups according to random number table, with 34 cases in each group. The patients in the control group were given teysuno, while the patients in the observation group were treated with teysuno combined with apatinib. The short-term efficacy, tumor markers[CA199, CA242, carcino-embryonic antigen (CEA)], and adverse reactions were compared between the two groups. Results The total relief rate and incidence of adverse reactions in observation group were higher than those in control group (P<0.05). After treatment, the levels of CA199, CA242, CEA in observation group were lower than those before treatment and control group(P<0.05). Conclusions Teysuno combined with apatinib is effective on advanced gastric cancer, which can decrease the levels of tumor markers, but it has more adverse reactions, so it should be carefully selected in the clinical application. Key words: Teysuno; Apatinib; Advanced gastric cancer; Tumor markers
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
